An Open-label Extension Trial to Evaluate the Long-term Safety of KVD900 (Sebetralstat) for On-Demand Treatment of Angioedema Attacks in Adolescent and Adult Patients With Hereditary Angioedema (HAE)
Public ClinicalTrials.gov record NCT05505916. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Official title
An Open-label Extension Trial to Evaluate the Long-term Safety of KVD900, an Oral Plasma Kallikrein Inhibitor, for On-demand Treatment of Angioedema Attacks in Adolescent and Adult Patients With Hereditary Angioedema Type I or II
Study identification
- NCT ID
- NCT05505916
- Recruitment status
- Active, not recruiting
- Study type
- Interventional
- Phase
- Phase 3
- Lead sponsor
- KalVista Pharmaceuticals, Ltd.
- Industry
- Enrollment
- 145 participants
Conditions and interventions
Conditions
Interventions
- KVD900 300 mg Drug
- KVD900 600 mg Drug
Drug
Eligibility (public fields only)
- Age range
- 12 Years and older
- Sex
- All
- Healthy volunteers
- Healthy volunteers not accepted
This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.
Study timeline
- Start date
- Oct 23, 2022
- Primary completion
- Jun 29, 2026
- Completion
- Jun 29, 2026
- Last update posted
- Feb 17, 2026
2022 – 2026
United States locations
- U.S. sites
- 20
- U.S. states
- 16
- U.S. cities
- 19
| Facility | City | State | ZIP | Site status |
|---|---|---|---|---|
| KalVista Investigative Site | Scottsdale | Arizona | 85251 | — |
| KalVista Investigative Site | Little Rock | Arkansas | 72205 | — |
| KalVista Investigative Site | San Diego | California | 92122 | — |
| KalVista Investigative Site | San Diego | California | 92123 | — |
| KalVista Investigative Site | Santa Monica | California | 90404 | — |
| KalVista Investigative Site | Centennial | Colorado | 80112 | — |
| KalVista Investigative Site | Colorado Springs | Colorado | 80907 | — |
| KalVista Investigative Site | Evansville | Indiana | 47715 | — |
| KalVista Investigative Site | Overland Park | Kansas | 66211 | — |
| KalVista Investigative Site | Louisville | Kentucky | 40215 | — |
| KalVista Investigative Site | Chevy Chase | Maryland | 20815 | — |
| KalVista Investigative Site | Plymouth | Minnesota | 55446 | — |
| KalVista Investigative Site | St Louis | Missouri | 63141 | — |
| KalVista Investigative Site | Charlotte | North Carolina | 28277 | — |
| KalVista Investigative Site | Cincinnati | Ohio | 45236 | — |
| KalVista Investigative Site | Toledo | Ohio | 43617 | — |
| KalVista Investigative Site | Hershey | Pennsylvania | 17033 | — |
| KalVista Investigative Site | Dallas | Texas | 75231 | — |
| KalVista Investgative Site | Layton | Utah | 84041 | — |
| KalVista Investigative Site | Spokane | Washington | 99204 | — |
Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.
Non-U.S. locations
This page focuses on the U.S. directory. The official record also lists 51 non-U.S. sites.
About this trial record page
- What this page shows
- Public field values for ClinicalTrials.gov record NCT05505916, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
- What this page does not do
- No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
- Where the data comes from
- Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
- Last refresh
- Last update posted Feb 17, 2026 · Synced May 16, 2026
Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.
Open the official record
The complete protocol, eligibility criteria, and contact information for NCT05505916 live on ClinicalTrials.gov.